News Releases

OTCQB: INTI
PRICE:
Stock Info
Advanced Search
  • Aug 21, 2015
    Enrollment commenced in HPPI’s Phase II(b) study of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome

    FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – August 21, 2015 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...

  • May 18, 2015
    HedgePath to shortly commence Phase II(b) skin cancer trial using Mayne Pharma’s SUBATM-Itraconazole

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (May 18, 2015) – HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers,...

  • Dec 16, 2014
    HPPI to commence Phase IIb study in first quarter 2015 of SUBATM-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome

    FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – December 16, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...

  • Nov 18, 2014
    Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome

    FOR IMMEDIATE RELEASE - TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – November 18, 2014 – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers,...

  • Jun 26, 2014
    Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital markets and public accounting expertise to HPPI’s board of directors

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (June 26, 2014) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers,...

Show 5102550100 per page
Get Important News and Updates by Email
* Required Fields